Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy - Transplantation and Cellular Therapy https://t.co/49QvZjf7QU
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma | Haematologica https://t.co/riQp8kUQ8X
Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis | Bone Marrow Transplantation https://t.co/SZamOz1c9q
Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation | Bone Marrow Transplantation https://t.co/QDI5rAyEMR
Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy—a guidance by the GoCART Coalition Pharmacist Working Group | Bone Marrow Transplantation https://t.co/HJYp7p78Ww
Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study | Bone Marrow Transplantation https://t.co/AeqS2hBjQQ
Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the EBMT https://t.co/6ZmtALdZFV